Dr. Martens (LON:DOCS) Announces Quarterly Earnings Results

Dr. Martens (LON:DOCS) announced its quarterly earnings results on Tuesday. The company reported GBX 4.20 earnings per share for the quarter, Digital Look Earnings reports. Dr. Martens had a net margin of 1.95% and a return on equity of 4.40%. The firm had revenue of £764.90 million for the quarter.

Here are the key takeaways from Dr. Martens’ conference call:

• Adjusted PBT rose 61% to £55.0 million reported, helped by stronger gross margin, tight cost control, and better revenue quality. The company also said net bank debt fell by £25 million, reinforcing balance sheet progress.
• Americas and APAC improved materially, with full-price DTC sales up 14% in the Americas and 15% in APAC. Management said this reflects a successful shift toward higher-quality revenue and less markdown dependence.
• EMEA remains the main weak spot, with DTC down amid a promotional market and weak consumer backdrop, especially in the U.K. and Germany. Management said completing the full-price pivot there is a key FY2027 focus and will likely create a near-term revenue headwind.
• Wholesale returned to growth for the first time since FY2023, supported by stronger order books for autumn/winter 2026. The company highlighted successful multi-year partnerships with retailers as a driver of that momentum.
• The brand and product pivot is gaining traction, with new families like Lowell, Buzz and Zebzag rising from 3% to 9% of pairs sold, while shoes grew 19% and bags 15%. Dr. Martens also said its organization is now streamlined and its new store formats are delivering higher average selling prices.

Dr. Martens Trading Up 3.8%

Shares of LON:DOCS opened at GBX 66.76 on Tuesday. The company’s 50-day moving average price is GBX 63.94 and its two-hundred day moving average price is GBX 71.49. Dr. Martens has a one year low of GBX 53.05 and a one year high of GBX 100.87. The company has a debt-to-equity ratio of 120.66, a current ratio of 2.18 and a quick ratio of 1.13. The stock has a market capitalization of £645.71 million, a PE ratio of 39.27, a price-to-earnings-growth ratio of 6.40 and a beta of 0.22.

Wall Street Analyst Weigh In

DOCS has been the subject of a number of research analyst reports. Berenberg Bank reduced their target price on shares of Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research note on Tuesday. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Dr. Martens in a research report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 110.

Insider Activity

In related news, insider Ije Nwokori sold 204,051 shares of Dr. Martens stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of GBX 66, for a total value of £134,673.66. Insiders bought a total of 930 shares of company stock valued at $59,984 over the last 90 days. 2.81% of the stock is currently owned by insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.